Heart Failure With Preserved Ejection Fraction: Clinical Trials

38 trials for Heart Failure With Preserved Ejection Fraction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 8 recruiting, 4 active not recruiting, 4 unknown. 38 Phase 2, 5 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 238Completed 16, Recruiting 8, Active not recruiting 4, Unknown 4, Terminated 3, Withdrawn 2, Enrolling by invitation 1
Phase 35Completed 4, Unknown 1
Phase 14Active not recruiting 1, Completed 1, Enrolling by invitation 1, Recruiting 1

Follow Heart Failure With Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction trials Research Report on Heart Failure With Preserved Ejection Fraction

Trials (filtered) newest first · largest first

All 38 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Colchicine, Placebo - Heart Failure With Preserved Ejection Fraction, Microvascular Coronary Artery Disease
Phase 2RecruitingMontreal Heart Institute642026-11-062026-11-10
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
HS235, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Phase 1 / Phase 2Recruiting35Pharma Inc., a GSK company1262026-10-212026-10-30
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg - Heart Failure With Preserved Ejection Fraction
Phase 2RecruitingEdgewise Therapeutics, Inc.902026-08-252026-10-13
EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)
Activin ligand-trap biological therapy, Placebo, Normal Saline - Heart Failure With Preserved Ejection Fraction
Phase 2RecruitingMassachusetts General Hospital482026-06-032026-07-09
A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction
HRS-1893 Tablet, HRS-1893 Tablet Placebo - Heart Failure With Preserved Ejection Fraction
Phase 2RecruitingShandong Suncadia Medicine Co., Ltd.482026-03-302026-05-11
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) - Heart Failure With Preserved Ejection Fraction
Phase 2RecruitingMayo Clinic352025-11-012026-07-08
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045- Dose A, TX000045- Dose B, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Phase 2Active not recruitingTectonic Therapeutic1912024-09-042026-07-07
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
HRS9531, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 2Active not recruitingFujian Shengdi Pharmaceutical Co., Ltd.2032024-05-062025-11-24
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
CDR132L, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 2WithdrawnCardior Pharmaceuticals GmbH2024-04-302026-07-07
Study of JK07 in Patients With Chronic Heart Failure
JK07, Placebo - Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Phase 2Active not recruitingSalubris Biotherapeutics Inc2822024-03-282026-05-22
The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED)
Colchicine, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 2UnknownTor Biering-Sørensen1522024-01-182024-02-28
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Dapagliflozin 10 MG [Farxiga] - Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction
Phase 1 / Phase 2Active not recruitingNorthwestern University182024-01-162026-07-30
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
Low calorie meal replacement plan, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography - Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic
Phase 2 / Phase 3CompletedUniversity of Leicester662023-12-052026-07-22
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
Metformin - Heart Failure With Preserved Ejection Fraction, Diabete Type 2
Phase 2 / Phase 3UnknownOctober University for Modern Sciences and Arts802023-11-012023-10-12
Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
Iohexol measurement, Geranylgeranylacetone (GGA), Echocardiography - Heart Failure With Preserved Ejection Fraction
Phase 2CompletedAmsterdam UMC, location VUmc432023-04-262025-04-01
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
LY3540378, Placebo - Heart Failure, Heart Failure With Preserved Ejection Fraction
Phase 2TerminatedEli Lilly and Company3322023-02-032026-02-05
Enhancing the Natriuretic Peptide System in HFpEF
MANP, Sacubitril/Valsartan, Oral Placebo - Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Phase 1 / Phase 2Enrolling by invitationHorng Chen602022-11-042025-10-09
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
HU6, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 2CompletedRivus Pharmaceuticals, Inc.672022-10-302024-08-26
Dapagliflozin With or Without Spironolactone for HFpEF
Dapagliflozin, Spironolactone + Dapagliflozin - Heart Failure With Preserved Ejection Fraction
Phase 2 / Phase 3CompletedUniversidade do Porto1082022-09-152025-08-17
Effectiveness of CRD-740 in Heart Failure
CRD-740, Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction
Phase 2TerminatedCardurion Pharmaceuticals, Inc.602022-05-262024-12-19

Showing 20 of 38. Sign in to see all of them.

Narrower conditions

Heart Failure (12)  ·  Cardiovascular Diseases (3)  ·  Heart Diseases (3)  ·  Hypertension, Pulmonary (3)  ·  Inflammation (3)  ·  Diabetes Mellitus, Type 2 (2)  ·  Heart Failure, Diastolic (2)  ·  Renal Insufficiency, Chronic (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Anemia, Iron-Deficiency (1)  ·  Atrial Fibrillation (1)  ·  Atrial Flutter (1)  ·  Cardiomegaly (1)  ·  Cardiomyopathy, Familial Restrictive, 3 (1)  ·  Euthyroid Sick Syndromes (1)

Broader conditions

Cardiovascular Diseases (15)  ·  Heart Diseases (12)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Pathologic Processes (6)  ·  Endocrine System Diseases (3)  ·  Hypertension (3)  ·  Lung Diseases (3)  ·  Metabolic Diseases (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Respiratory Tract Diseases (3)  ·  Urogenital Diseases (3)  ·  Vascular Diseases (3)  ·  Chronic Disease (2)  ·  Diabetes Mellitus (2)  ·  Disease Attributes (2)

Interventions

dapagliflozin (3)  ·  sacubitril and valsartan sodium hydrate drug combination (3)  ·  Colchicine (2)  ·  Echocardiography (2)  ·  Electrocardiography (2)  ·  Metformin (2)  ·  Potassium Chloride (2)  ·  Saline Solution (2)  ·  potassium nitrate (2)  ·  68Ga-FAPI (1)  ·  AZD4831 (1)  ·  Cilostazol (1)  ·  Diagnostic Imaging (1)  ·  Diet (1)  ·  Hematologic Tests (1)

Sponsors

University of Pennsylvania (4)  ·  Massachusetts General Hospital (3)  ·  Cardurion Pharmaceuticals, Inc. (2)  ·  Mayo Clinic (2)  ·  35Pharma Inc., a GSK company (1)  ·  Actelion (1)  ·  Akebia Therapeutics (1)  ·  Amsterdam UMC, location VUmc (1)  ·  AstraZeneca (1)  ·  Barry Borlaug (1)  ·  Bristol-Myers Squibb (1)  ·  Cardior Pharmaceuticals GmbH (1)  ·  Chongqing Medical University (1)  ·  Edgewise Therapeutics, Inc. (1)  ·  Eli Lilly and Company (1)

Countries

United States (26)  ·  Canada (7)  ·  China (5)  ·  Poland (4)  ·  United Kingdom (4)  ·  Brazil (3)  ·  Bulgaria (3)  ·  Czechia (3)  ·  Denmark (3)  ·  Hungary (3)  ·  Israel (3)  ·  Spain (3)  ·  Argentina (2)  ·  Australia (2)  ·  Austria (2)

Top investigators

Payman Zamani, MD (2)  ·  Adelino Leite-Moreira, MD, PhD (1)  ·  Adriaan Voors, MD, PhD (1)  ·  Anne R Cappola, MD,ScM (1)  ·  Barry A Borlaug (1)  ·  Barry Borlaug, MD (1)  ·  Bing Deng, M.D (1)  ·  Camilla Ikast Ottosen, MD (1)  ·  Dalane W. Kitzman, MD (1)  ·  Gerry P McCann, MD (1)  ·  Greg Lewis, MD (1)  ·  Gregorio Tersalvi, M.D (1)  ·  Gregory D. Lewis, MD (1)

Results publications

PMID 25344549, PMID 26449137, PMID 28993402, PMID 29523517, PMID 30842316, PMID 31132875, PMID 31932459, PMID 32105984, PMID 32535122, PMID 33079154, PMID 33421267, PMID 33879223, PMID 37470101, PMID 37534453, PMID 39046727, PMID 39101201, PMID 39347697, PMID 39552153, PMID 39880434, PMID 40066571, PMID 40072462, PMID 40243975, PMID 40738559, PMID 40887551, PMID 41171251, PMID 42201301, PMID 42717033

NIH funding

2016 (1), 2023 (1), K23HL150236 (1), R01HL151841 (1), R61HL146390 (1), U01AG076928 (1)